-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Voyager Therapeutics, Lowers Price Target to $12

Benzinga·03/13/2025 16:15:46
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy and lowers the price target from $14 to $12.